Amylyx Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.38 billion
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Amylyx Pharmaceuticals Inc had its IPO on 2022-01-07 under the ticker symbol AMLX.
The company operates in the Healthcare sector and Biotechnology industry. Amylyx Pharmaceuticals Inc has a staff strength of 237 employees.
Shares of Amylyx Pharmaceuticals Inc opened at $28.78 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $27.63 - $29.16, and closed at $28.74.
This is a -1.03% slip from the previous day's closing price.
A total volume of 917,900 shares were traded at the close of the day’s session.
In the last one week, shares of Amylyx Pharmaceuticals Inc have slipped by -10.41%.
Amylyx Pharmaceuticals Inc's Key Ratios
Amylyx Pharmaceuticals Inc has a market cap of $2.38 billion, indicating a price to book ratio of 16.3998 and a price to sales ratio of 6725.4844.
In the last 12-months Amylyx Pharmaceuticals Inc’s revenue was $345000 with a gross profit of $-43755000 and an EBITDA of $-184736000. The EBITDA ratio measures Amylyx Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amylyx Pharmaceuticals Inc’s operating margin was -53641.45% while its return on assets stood at -74.17% with a return of equity of -141.93%.
In Q3, Amylyx Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.1%.
Amylyx Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amylyx Pharmaceuticals Inc’s profitability.
Amylyx Pharmaceuticals Inc stock is trading at a EV to sales ratio of 6394.7802 and a EV to EBITDA ratio of -11.6129. Its price to sales ratio in the trailing 12-months stood at 6725.4844.
Amylyx Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $181.44 million
- Total Liabilities
- $32.65 million
- Operating Cash Flow
- $84.04 million
- Capital Expenditure
- Dividend Payout Ratio
Amylyx Pharmaceuticals Inc ended 2023 with $181.44 million in total assets and $0 in total liabilities. Its intangible assets were valued at $181.44 million while shareholder equity stood at $144.03 million.
Amylyx Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $32.65 million in other current liabilities, 6000.00 in common stock, $-311516000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $107.73 million and cash and short-term investments were $162.59 million. The company’s total short-term debt was $1,990,000 while long-term debt stood at $0.
Amylyx Pharmaceuticals Inc’s total current assets stands at $172.20 million while long-term investments were $0 and short-term investments were $54.86 million. Its net receivables were $137000.00 compared to accounts payable of $7.05 million and inventory worth $563000.00.
In 2023, Amylyx Pharmaceuticals Inc's operating cash flow was $84.04 million while its capital expenditure stood at $459000.
Comparatively, Amylyx Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Amylyx Pharmaceuticals Inc stock is currently trading at $28.74 per share. It touched a 52-week high of $41.93 and a 52-week low of $41.93. Analysts tracking the stock have a 12-month average target price of $48.4.
Its 50-day moving average was $35.09 and 200-day moving average was $30.56 The short ratio stood at 6.17 indicating a short percent outstanding of 0%.
Around 2456.8% of the company’s stock are held by insiders while 8253.4% are held by institutions.
Frequently Asked Questions About Amylyx Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.